Amgen's new drug could mean fewer shots for obesity patients

Amgen (AMGN) is developing MariTide, an obesity drug requiring fewer injections than competitors like Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound. Amgen's Q3 revenue rose 8% to $10.4B, with EPS up 14% to $6.45, beating estimates. The company raised its full-year EPS guidance to $22.90-$23.70. MariTide's Phase 3 trials will be critical for Amgen's long-term valuation.

Original reporting

finance.yahoo.com

Published Nov 8, 2026, 10:47 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 8, 2026, 11:09 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Amgen's new drug could mean fewer shots for obesity patients — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$AMGNBullishHigh

Why it matters

The earnings beat and guidance lift reinforce confidence in Amgen's existing products and underscore the high stakes of the MariTide trial for future growth.

Market read

Amgen's earnings beat and raised outlook provide a fresh catalyst for the stock and may reshape expectations for the obesity‑drug market.

What to watch

The guidance raise assumes successful trial outcomes; any delay or safety issue could reverse the upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Amgen highlighted its broader portfolio performance, noting strong sales from Repatha, UPLIZNA, and IMDELLTRA, while emphasizing the strategic importance of its obesity candidate MariTide.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNBullishHigh confidence

Context

Amgen posted Q3 revenue of $10.4B and EPS $6.45, beating estimates, and raised its full-year adjusted earnings guidance to $22.90‑$23.70 per share.

Expected impact

likely upward pressure as investors price in stronger earnings and higher outlook

Evidence & confidence

The beat and guidance raise are fresh primary disclosures for a large‑cap biotech, which historically drive short‑term price gains.

Market effects

Sector

Weight‑loss market dynamics may shift if Amgen's monthly/quarterly dosing succeeds, pressuring Novo Nordisk and Eli Lilly.

Regional

U.S. biotech sector may see modest rally on the earnings beat.

Global

Potential to influence global obesity‑drug pipeline valuations.

Counterpoint

What could challenge this read

If Phase 3 data disappoint, the raised guidance could be unsustainable, leading to a pull‑back.

Key entities

company
Amgen
US‑listed biotech (ticker AMGN) reporting Q3 results and obesity‑drug trial progress.
company
Novo Nordisk
Competitor in the weekly injection weight‑loss market.
company
Eli Lilly
Competitor with Zepbound in the obesity space.

Read at source ← All news

$AMGNHigh

FDA Approval for KANJINTI issued to AMGEN INC

Amgen (AMGN) received FDA approval for its biosimilar KANJINTI (trastuzumab-anns) on November 9, 2026. The company's stock has shown varied reactions to past FDA approvals and other news, with a median move of 1.2% in either direction. Amgen is a biotechnology company focused on biological products.

quantisnow.comNov 10

$AMGNMedAI 8/10

Amgen Highlights Repatha's Cost-Effectiveness, Long-Term Cardiovascular Benefits

Amgen (AMGN) presented data at the AHA Scientific Sessions 2026, showing Repatha (evolocumab) is cost-effective and reduces cardiovascular risk. Analyses found a 39% reduction in major adverse cardiovascular events in CKD patients and sustained benefits over 8 years. AMGN stock is up 1.04% to $465.23.

rttnews.comNov 10

$AMGNMed

NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM

Amgen presented data at AHA 2026 showing Repatha's cost-effectiveness in high-risk patients without prior heart attacks or strokes, with a 29% lower risk of major cardiovascular events in ASCVD patients. The VESALIUS-CV and FOURIER trials demonstrated Repatha's long-term benefits, including a 39% reduction in MACE in CKD patients and a 29% lower rate of 3-P MACE over 8 years.

prnewswire.comNov 9

$ENBMedAI 8/10

Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated

Major U.S. indices fell last week, with the Nasdaq down 3.37% and S&P 500 off 2.68%. The CBOE Volatility Index settled at 23.5. Enbridge reported Q3 earnings of $0.59 per share, Amgen saw 8% revenue growth, Thomson Reuters reported 10% revenue growth, Sun Life Financial increased underlying net income by 9%, and Eli Lilly partnered with Hims & Hers.

prnewswire.comNov 9

$NVSHigh

Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals

Novartis and Ionis reported that pelacarsen failed to reduce cardiovascular events in the HORIZON trial, despite lowering lipoprotein(a) levels. Analysts see a challenging path for Lp(a)-targeting therapies, including Amgen's olpasiran and Eli Lilly's lepodisiran. Novartis' stock was impacted, and analysts lowered success probabilities for competitors' drugs. The trial results raise questions about the viability of Lp(a) targeting in cardiovascular disease.

biospace.comNov 9